Literature DB >> 29568697

Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion.

Desi P Schoo1, Grace X Tan1, Matthew R Ehrenburg1, Seth E Pross1, Bryan K Ward1, John P Carey1.   

Abstract

PURPOSE OF REVIEW: Aminoglycosides and corticosteroids are commonly used to treat Menière's disease. Intratympanic (IT) administration of these medications allows high inner ear concentrations without significant adverse systemic effects. As a direct result, IT therapy has grown in popularity. Recent studies have compared patient outcomes between IT aminoglycosides and corticosteroids. This review summarizes these findings. RECENT
FINDINGS: Trials comparing IT corticosteroids to IT placebo or oral therapy have had conflicting results. Most recently, Lambert et al. investigated the effect of IT dexamethasone in a sustained-release formulation compared to placebo. Their findings demonstrated improvement in some secondary measures of vertigo with the sustained-release formulation.IT gentamicin is known to be effective in controlling vertigo in Menière's disease. In a recent study from 2016, Patel et al compared IT gentamicin and IT methylprednisolone in a double-blind, randomized controlled trial and identified no significant differences between the two in vertigo control.
SUMMARY: IT injections of aminoglycosides and corticosteroids can improve vertigo control. Hearing and vestibular loss however may result with IT aminoglycosides. Corticosteroids demonstrate limited hearing loss but may not have the same efficacy in controlling vertigo. Further investigation in the etiology of Menière's disease is needed to tailor the proposed treatment to suit the disease mechanism.

Entities:  

Keywords:  Menière's disease; aminoglycosides; corticosteroids; intratympanic

Year:  2017        PMID: 29568697      PMCID: PMC5857942          DOI: 10.1007/s40136-017-0153-5

Source DB:  PubMed          Journal:  Curr Otorhinolaryngol Rep


  104 in total

Review 1.  Chemical and physical labyrinthectomy for Meniere's disease.

Authors:  Wayne E Berryhill; Malcolm D Graham
Journal:  Otolaryngol Clin North Am       Date:  2002-06       Impact factor: 3.346

Review 2.  Intratympanic gentamicin for Ménière's disease or syndrome.

Authors:  Bas Pullens; Peter Paul van Benthem
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

3.  Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial.

Authors:  Marco Antonio Garduño-Anaya; Heloísa Couthino De Toledo; Ramón Hinojosa-González; Carlo Pane-Pianese; Luis Camilo Ríos-Castañeda
Journal:  Otolaryngol Head Neck Surg       Date:  2005-08       Impact factor: 3.497

4.  Ototoxicity of gentamicin.

Authors:  J Wersäll; P G Lundquist; B Björkroth
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

5.  Perilymph pharmacokinetics of locally-applied gentamicin in the guinea pig.

Authors:  A N Salt; J J Hartsock; R M Gill; E King; F B Kraus; S K Plontke
Journal:  Hear Res       Date:  2016-10-08       Impact factor: 3.208

6.  Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Ménière's disease: a prospective, double-blind, placebo-controlled, randomized clinical trial.

Authors:  Robert Stokroos; Herman Kingma
Journal:  Acta Otolaryngol       Date:  2004-03       Impact factor: 1.494

7.  Intratympanic application of an antiviral agent for the treatment of Ménière's disease.

Authors:  Jean-Philippe Guyot; Raphael Maire; Olga Delaspre
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2008-02-01       Impact factor: 1.538

8.  Placebo effect in surgery for Ménière's disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery.

Authors:  J Thomsen; P Bretlau; M Tos; N J Johnsen
Journal:  Arch Otolaryngol       Date:  1981-05

9.  Secondary apoptosis of spiral ganglion cells induced by aminoglycoside: Fas-Fas ligand signaling pathway.

Authors:  Woo Yong Bae; Lee Suk Kim; Dae Young Hur; Sung Wook Jeong; Jae Ryong Kim
Journal:  Laryngoscope       Date:  2008-09       Impact factor: 3.325

10.  Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).

Authors:  Christine Adrion; Carolin Simone Fischer; Judith Wagner; Robert Gürkov; Ulrich Mansmann; Michael Strupp
Journal:  BMJ       Date:  2016-01-21
View more
  4 in total

1.  Dexamethasone and Dexamethasone Phosphate Entry into Perilymph Compared for Middle Ear Applications in Guinea Pigs.

Authors:  Alec N Salt; Jared J Hartsock; Fabrice Piu; Jennifer Hou
Journal:  Audiol Neurootol       Date:  2018-11-29       Impact factor: 1.854

Review 2.  Vestibular Disorders.

Authors:  Michael Strupp; Julia Dlugaiczyk; Birgit Bettina Ertl-Wagner; Dan Rujescu; Martin Westhofen; Marianne Dieterich
Journal:  Dtsch Arztebl Int       Date:  2020-04-24       Impact factor: 5.594

Review 3.  Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis.

Authors:  Weiming Hao; Huiqian Yu; Huawei Li
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

Review 4.  Developments in Bio-Inspired Nanomaterials for Therapeutic Delivery to Treat Hearing Loss.

Authors:  Christopher Rathnam; Sy-Tsong Dean Chueng; Yu-Lan Mary Ying; Ki-Bum Lee; Kelvin Kwan
Journal:  Front Cell Neurosci       Date:  2019-11-06       Impact factor: 5.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.